CatSci has made a “significant” investment to support the development of oligonucleotide capability at its site in Cardiff, UK. This follows recent investment in the firm by Keensight Capital to support its strategic growth plans.
Indian Prime Minister Narendra Modi has laid the foundation stone of a ‘bulk drug park’ at Haroli in the Una district of the northern state of Himachal Pradesh state. In doing so, he said that the park will help to “reduce dependence on API imports”.
Ecolab subsidiary Purolite has held a ribbon-cutting ceremony to mark the tripling of agarose resin capacity at its 10,855 m2 site at Llantrisant, near Cardiff, UK. The resins are made from red seaweed in beads varying between 35 and 200 microns in size, using a “jetted” manufacturing process that is said to significantly reduces the steps and time required to produce resin, while reducing the overall carbon footprint.
Merck KGaA has revealed at its latest Capital Markets Day that it will continue to focus on its ‘Big Three’ businesses of Process Solutions and Life Science Services, new products in Healthcare and the Semiconductor Solutions arm.
By 2025, these are expected to generate about 80% of targeted sales growth, and more than 50% of total sales. The company remains on track to achieve its mid-term growth target of €25 billion that year and expects to increase sales organically by at least 6%/year on average, about €1 billion/year.
Peptides giant Bachem has agreed to acquire an undeveloped site covering 155,000 m2 in Sisslerfeld, north-western Switzerland, from DSM in order to manage growing demand. It has already acquired the first plot and others will follow in time. Terms are not being disclosed.
Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.
Lonza has completed the expansion of a multi-purpose. kilogram-scale HPAPI manufacturing suite at its main site in Visp, Switzerland. This adds development and manufacturing capacity for ADC payloads, “supporting the entire development and manufacturing pipeline from feasibility studies to commercial supply”.
